Drug With a 30-Year Monopoly Is Target of State-Level Push to Curb Prices
https://www.profitableratecpm.com/f4ffsdxe?key=39b1ebce72f3758345b2155c98e6709c
In a first, Colorado will cap the price of Enbrel, an arthritis drug. Using patent tactics, pharmaceutical manufacturer Amgen has aggressively blocked competition for this product.
